Hengrui Pharmaceutical announced that the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. has received the HRS-1596 “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and will conduct clinical trials for weight management indications and type 2 diabetes indications in the near future. HRS-1596 tablets are a Class 1 new drug independently developed by the company. No oral drug with the same target has been approved for marketing at home or abroad. Up to now, the total R&D investment for related projects is about 18.4 million yuan. The drug still needs to be clinically tested and approved before it can be manufactured and marketed, and there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.